Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

NCT03061539 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

380

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Nivolumab & Ipilimumab

Sponsor

University College, London

Collaborators

[object Object]